ID: ALA5182165

Max Phase: Preclinical

Molecular Formula: C8H7BrN4S

Molecular Weight: 271.14

Associated Items:

Representations

Canonical SMILES:  Nn1c(-c2ccc(Br)cc2)n[nH]c1=S

Standard InChI:  InChI=1S/C8H7BrN4S/c9-6-3-1-5(2-4-6)7-11-12-8(14)13(7)10/h1-4H,10H2,(H,12,14)

Standard InChI Key:  IGIGQDMDHXLNRL-UHFFFAOYSA-N

Associated Targets(non-human)

Urease 750 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 271.14Molecular Weight (Monoisotopic): 269.9575AlogP: 2.08#Rotatable Bonds: 1
Polar Surface Area: 59.63Molecular Species: NEUTRALHBA: 4HBD: 2
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.51CX Basic pKa: 3.31CX LogP: 2.66CX LogD: 2.43
Aromatic Rings: 2Heavy Atoms: 14QED Weighted: 0.62Np Likeness Score: -2.02

References

1. Yang W, Feng Q, Peng Z, Wang G..  (2022)  An overview on the synthetic urease inhibitors with structure-activity relationship and molecular docking.,  234  [PMID:35305460] [10.1016/j.ejmech.2022.114273]

Source